CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Nanodox 1% (doxycycline monohydrate hydrogel)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02910011
NCT02910011Phase 2Completed
CompareCT.gov

A Phase 2, Exploratory Study to Investigate Safety and Efficacy of Doxycycline Monohydrate Hydrogel (NANODOX® HYDROGEL 1%) In Atopic Dermatitis

University of Florida·interventional·Posted Sep 21, 2016·Updated Mar 26, 2020

In Brief

A Phase 2 clinical trial evaluating Nanodox 1% (doxycycline monohydrate hydrogel) for Dermatitis, Atopic. Completed, enrolled 23 participants across 2 sites.

Detailed Summary

This study will investigate the safety and clinical efficacy of a novel doxycycline topical formulation in subjects with Atopic Dermatitis (AD). The investigators hypothesize that daily application of the study drug in AD subjects will reduce severity of the disease, by reducing skin driven inflammation and restoring skin barrier function. The investigators will also monitor the anti-microbial activity of this product on AD skin, as colonization with Staph aureus is typically associated with disease severity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesUnited States
CollaboratorsAlchem Laboratories, Inc

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 21, 2016
Enrollment StartMay 18, 2017
Primary CompletionNov 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.8 years ago

Interventions

Nanodox 1% (doxycycline monohydrate hydrogel)drug

Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner